Research programme: HIV vaccines - GenVec

Drug Profile

Research programme: HIV vaccines - GenVec

Alternative Names: HIV adenovector serotype Ad41 vaccine - GenVec/NIAID; Second-generation HIV vaccines - GenVec/SAIC-Frederick

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GenVec
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 16 Jun 2017 GenVec was acquired by Intrexon Corporation
  • 28 Mar 2014 Discontinued - Preclinical for HIV-1 infections in USA (Parenteral)
  • 04 Sep 2013 Research programme: HIV vaccines - GenVec is available for licensing as of 04 Sep 2013. http://www.genvec.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top